Get the Stockscreener App
4.07
2.52%
0.10
After Hours:
4.07
Opthea Limited Adr stock is traded at $4.07, with a volume of 47,138.
It is up +2.52% in the last 24 hours and up +31.90% over the past month.
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.
See More
Previous Close:
$3.97
Open:
$3.87
24h Volume:
47,138
Relative Volume:
2.89
Market Cap:
$626.32M
Revenue:
$117.10K
Net Income/Loss:
$-161.61M
P/E Ratio:
-1.6761
EPS:
-2.4283
Net Cash Flow:
-
1W Performance:
+4.36%
1M Performance:
+31.90%
6M Performance:
-0.97%
1Y Performance:
+133.64%
1-Day Range:
$3.87
$4.16
1-Week Range:
$3.59
$4.30
52-Week Range:
$1.60
$4.40
Opthea Limited Adr Stock (OPT) Company Profile
Opthea Limited Adr Stock (OPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-08-22 | Initiated | H.C. Wainwright | Buy |
| Apr-26-22 | Initiated | SVB Leerink | Outperform |
| Nov-17-20 | Initiated | Citigroup | Buy |
| Nov-11-20 | Initiated | Oppenheimer | Outperform |
| Nov-11-20 | Initiated | SVB Leerink | Outperform |
| Nov-11-20 | Initiated | Truist | Buy |
View All
Opthea Limited Adr Stock (OPT) Latest News
Opthea to Participate in the UBS Virtual Ophthalmology Day 2024 - The Manila Times
Opthea to Participate in the UBS Virtual Ophthalmology Day 2024 - StockTitan
Opthea Advances Retinal Disease Treatments - TipRanks
Opthea Advances nAMD Treatment with Sozinibercept - TipRanks
Opthea Limited (NASDAQ:OPT) Shares Sold by Victory Capital Management Inc. - Defense World
EX-99.1 - SEC.gov
Opthea Advances Toward Sozinibercept Commercialization - TipRanks
Opthea’s Sozinibercept Eyes Breakthrough in AMD Therapy - TipRanks
FY2025 EPS Estimates for Opthea Limited Boosted by HC Wainwright (NASDAQ:OPT) - Defense World
Research Analysts Set Expectations for Opthea Limited’s FY2029 Earnings (NASDAQ:OPT) - Defense World
Opthea Prepares for Phase 3 Results with Leadership Revamp - TipRanks
Opthea (NASDAQ:OPT) Given New $12.00 Price Target at HC Wainwright - Defense World
Opthea Limited Showcases Innovations at Investor Conferences - TipRanks
Opthea Limited: Revenues Up, Losses Widen - TipRanks
Opthea Reports Full-Year Financial Results and Business Updates - Morningstar
Opthea to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15, 2024 - Morningstar
Opthea Limited Showcases at Ophthalmology Event - TipRanks
OPTOpthea Limited Latest Stock News & Market Updates - StockTitan
Opthea forms global medical advisory board for retinal diseases - Investing.com India
Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board - StockTitan
Opthea forms global medical advisory board for retinal diseases - Investing.com
Why Atturra, Bravura, Core Lithium, and Opthea shares are racing higher today - The Motley Fool
Opthea’s Sozinibercept Shows Promise for Wet AMD - TipRanks
Opthea Announces Publication on VEGF-C and D Signaling Pathways as Potential Targets for Treatment of Wet AMD - StockTitan
Opthea (NASDAQ:OPT) Shares Down 0.8% - Defense World
Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022 - The Globe and Mail
Opthea To Present at SVB Leerink Global Healthcare Conference - The Globe and Mail
Opthea strengthens its Board of Directors - Quantisnow
Optiva Wins Prestigious "Enterprise eSIM Solution of the Year" Award - GlobeNewswire Inc.
Optiva Inc. Announces Results of Annual and Special Meeting - GlobeNewswire Inc.
Opthea A$55.0m (US$36.9m¹) Retail Entitlement Offer Opens - GlobeNewswire Inc.
Opthea A$55.0m (US$36.9m¹) Retail Entitlement Offer Opens - Morningstar
Opthea raises $113.2 million to fund eye drug development - The Pharma Letter
Opthea Successfully Completes Placement and Institutional Component of Entitlement Offer Raising A$171.5 million (US$113.2m¹) - GlobeNewswire Inc.
Opthea Successfully Completes Placement and Institutional Component of Entitlement Offer Raising A$171.5 million (US$113.2m¹) - Morningstar
Opthea Announces Placement and Partially Underwritten Entitlement Offer to Raise up to Approximately A$227.3 million (US$150.0 million¹) - GlobeNewswire Inc.
Opthea To Present at Clinical Trials at the Summit Meeting - GlobeNewswire Inc.
Opthea LimitedADR (OPT) Price Target Increased by 9.06% to 5.95 - MSN
Market Insight: Opthea Limited ADR (OPT)'s Notable Drop, Closing at 3.00 – DWinneX - The Dwinnex
2 Stocks Under $10 Wall Street Says Are 'Strong Buys' - Barchart
Opthea Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD - GlobeNewswire Inc.
Opthea (NASDAQ:OPT) Shares Down 0.6% - Defense World
Optiva Inc. Reports First Quarter 2024 Financial Results - GlobeNewswire Inc.
Opthea Announces Upcoming Presentations at the Retina World Congress 2024 - GlobeNewswire Inc.
Optiva and GDi Announce Strategic Partnership to Deliver Integrated BSS and OSS Solutions - GlobeNewswire Inc.
Opthea Appoints John Han, PharmD, as VP Medical Affairs - GlobeNewswire Inc.
Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference By Investing.com - Investing.com South Africa
Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference - GlobeNewswire Inc.
Opthea Appoints Sujal Shah to the Board of Directors - GlobeNewswire Inc.
Opthea appoints new director and audit chair By Investing.com - Investing.com
11 Best ASX Stocks To Buy Now - Yahoo Finance
Opthea Limited Adr Stock (OPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):